KUALA LUMPUR, Manulife Malaysia is stepping up its focus on cancer prevention through new insurance-led health protection initiatives.
MANULIFE, Chief Marketing Officer Marilyn Wang.
Chief Marketing Officer Marilyn Wang said the move aims to support Malaysians throughout their entire health journey.
“We want to be more than just a claims processor. Our goal is to be a true health partner—raising awareness, promoting early detection, providing treatment support, and ensuring continued care after recovery,” Wang said at a media briefing today.
She highlighted that this commitment is reflected in Manulife’s flagship products, Manulife HealthSave Enrich (MHSE) and Beyond Critical Cover (BCC).
Life insurer Manulife Malaysia is deepening its commitment to cancer prevention through insurance-led health protection.
“MHSE and BCC are designed to close key gaps in health literacy, vaccine uptake, and post-diagnosis care,” she explained.
MHSE offers coverage for preventive vaccines such as HPV, dengue, and influenza, alongside benefits like up to a 40% no-claims discount, outpatient care, post-cancer recovery support, and annual family coverage of up to RM20 million.
BCC provides upfront financial payouts upon diagnosis of any of 48 covered critical illnesses, as well as additional support for ICU admissions and extended hospital stays.
Wang noted the approach is supported by findings from the Asia Care Survey 2024, which revealed that 45% of Malaysians are concerned about cancer and 71% feel underinsured for treatment costs.
“Many are unaware that HPV vaccines are available for free in public schools. We want to change that by promoting awareness, encouraging prevention, and helping people take action before it’s too late,” she added.
The initiative also complements the efforts of Cancer Research Malaysia (CRM), which is dedicated to advancing cancer research and development in the region.
Cancer is currently the fourth leading cause of death in Malaysia, according to the Department of Statistics. CRM projects that cancer incidence could double by 2040, with one in nine women and one in ten men expected to be diagnosed in their lifetime.
